BioCentury | Sep 10, 2018
Distillery Therapeutics

Inflammation

...INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat...
...of a 28-amino acid, cell-penetrating peptide from the N-terminus of Drosophila antennapedia (Antp) and an LTBR-binding...
...the classical and non-classical NF-κB pathways. In mouse lymphatic endothelial cells, the fusion peptide decreased TRAF3-LTBR...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Autoimmune disease

...INDICATION: Scleroderma Mouse and cell cultures studies suggest agonizing LTBR in adipose-derived mesenchymal stromal cell (ADSC...
...LTB expression. In cultured mouse or human ADSCs, a mouse or human agonist antibody against LTBR...
...include testing the ADSC-LTBR agonist antibody therapy in additional scleroderma models. TARGET/MARKER/PATHWAY: Lymphotoxin β receptor (LTBR...
BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: Leukotriene B4 type 1 receptor (BLT1; LTB4R)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest inhibiting LTB4R could help treat Type II diabetes. In mice fed a high-fat diet, LTB4R knockout or a small molecule LTB4R inhibitor increased glucose tolerance...
BioCentury | Oct 23, 2014
Distillery Therapeutics

Indication: Cancer

...Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Lymphotoxin-a (LTa); lymphotoxin-b receptor (LTBR...
...chemokine CXC motif ligand 13 (CXCL13); CXC chemokine receptor 5 (CXCR5) Mouse studies suggesting inhibiting LTa-LTBR...
...treat CLL. In a mouse model of CLL, Lta secreted by leukemia cells interacted with Ltbr...
BioCentury | Mar 27, 2014
Distillery Therapeutics

Indication: Infectious disease

...Publication and contact information Infectious disease HBV Lymphotoxin-b receptor (LTBR) In vitro studies suggest activating LTBR...
...from eradicating the virus. In multiple cell culture models of HBV infection, antibody agonists of LTBR...
...with mock treatment or human IgG. Next steps could include understanding the mechanism by which LTBR...
BioCentury | Aug 29, 2011
Strategy

R&D reboot

...in the U.S. in March and Europe in July Baminercept Extracellular domain of the lymphotoxin beta receptor (LTBR...
BioCentury | May 5, 2011
Cover Story

LIGHTs out for asthma

...14 ( TNFRSF14 ; LIGHTR ; HVEM ) and lymphotoxin b receptor ( LTBR ; LTbR...
...of IgG and the extracellular portion of Ltbr that inhibits Light's interactions with its receptors, Ltbr...
...smooth muscle hyperplasia and airway hyperresponsiveness were achieved by simultaneous delivery of the fusion protein Ltbr-Fc...
BioCentury | Apr 28, 2011
Distillery Therapeutics

Indication: Inflammation

...decreasing airway remodeling. In two mouse models of allergen-induced chronic asthma, a Light inhibitor called Ltbr-Fc...
...that contains the IgG Fc chain and one of Light's receptors, lymphotoxin b receptor (Ltbr; Ltbr...
BioCentury | Apr 8, 2010
Distillery Therapeutics

Indication: Infectious disease

...Infectious disease Bacterial infection Lymphotoxin-b receptor (LTBR) In vitro and mouse studies suggest that upregulating LTBR...
...Ltbr-deficient bone marrow increased bacterial titers compared with administration of normal bone marrow. In infected Ltbr...
...Next steps could include identifying an LTBR activator to test the therapeutic potential of upregulating LTBR...
BioCentury | Mar 25, 2010
Distillery Therapeutics

Indication: Cancer

...Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Lymphotoxin-b (LTb); LTb receptor (LTBR...
Items per page:
1 - 10 of 28